...
首页> 外文期刊>Acta Neuropathologica Communications >Expression of renal cell markers and detection of 3p loss links endolymphatic sac tumor to renal cell carcinoma and warrants careful evaluation to avoid diagnostic pitfalls
【24h】

Expression of renal cell markers and detection of 3p loss links endolymphatic sac tumor to renal cell carcinoma and warrants careful evaluation to avoid diagnostic pitfalls

机译:肾细胞标志物的表达和3p缺失的检测将淋巴囊囊性肿瘤与肾细胞癌联系起来,需要仔细评估以避免诊断缺陷

获取原文

摘要

Endolymphatic sac tumor (ELST) is a rare neoplasm arising in the temporal petrous region thought to originate from endolymphatic sac epithelium. It may arise sporadically or in association with Von-Hippel-Lindau syndrome (VHL). The ELST prevalence in VHL ranges from 3 to 16% and may be the initial presentation of the disease. Onset is usually in the 3rd to 5th decade with hearing loss and an indolent course. ELSTs present as locally destructive lesions with characteristic computed tomography imaging features. Histologically, they show papillary, cystic or glandular architectures. Immunohistochemically, they express keratin, EMA, and variably S100 and GFAP. Currently it is recommended that, given its rarity, ELST needs to be differentiated from other entities with similar morphologic patterns, particularly other VHL-associated neoplasms such as metastatic clear cell renal cell carcinoma (ccRCC). Nineteen ELST cases were studied. Immunohistochemistry (18/19) and single nucleotide polymorphism microarray testing was performed (12/19). Comparison with the immunophenotype and copy number profile in RCC is discussed. Patients presented with characteristic bone destructive lesions in the petrous temporal bones. Pathology of tumors showed characteristic ELST morphology with immunoexpression of CK7, GFAP, S100, PAX-8, PAX-2, CA-9 in the tumor cells. Immunostaines for RCC, CD10, CK20, chromogranin A, synaptophysin,?TTF-1, thyroglobulin, and transthyretin were negative in the tumor cells. Molecular testing showed loss of 3p and 9q in 66% (8/12) and 58% (7/12) cases, respectively. Immunoreactivity for renal markers in ELST is an important diagnostic caveat and has not been previously reported. In fact, renal markers are currently recommended in order to rule out metastatic RCC although PAX gene complex and CA-9 have been implicated in the development of the inner ear. Importantly copy number assessment of ELST has not been previously reported. Loss of 3p (including the VHL locus) in ELST suggests similar mechanistic origins as ccRCC.
机译:内淋巴囊肿瘤(ELST)是一种罕见的赘生物,出现在颞骨小区域,被认为起源于内淋巴囊上皮。它可能偶发或与Von-Hippel-Lindau综合征(VHL)合并出现。 VHL中ELST的患病率为3%至16%,可能是该疾病的最初表现。发病通常在第3至第5个十年,伴有听力损失和顽固的病程。 ELST表现为具有特征性计算机断层摄影成像特征的局部破坏性病变。从组织学上看,它们表现出乳头状,囊性或腺体结构。在免疫组织化学上,它们表达角蛋白,EMA和S100和GFAP。当前,建议考虑到其稀有性,需要将ELST与具有相似形态特征的其他实体区分开,尤其是其他VHL相关肿瘤,例如转移性透明细胞肾细胞癌(ccRCC)。研究了19例ELST病例。进行了免疫组织化学(18/19)和单核苷酸多态性微阵列测试(12/19)。讨论了与RCC中免疫表型和拷贝数分布的比较。患者在颞骨有特征性的骨破坏性病变。肿瘤病理表现出特征性的ELST形态,在肿瘤细胞中具有CK7,GFAP,S100,PAX-8,PAX-2,CA-9的免疫表达。在肿瘤细胞中,RCC,CD10,CK20,嗜铬粒蛋白A,突触素,ΔTTF-1,甲状腺球蛋白和运甲状腺素蛋白的免疫染色均为阴性。分子测试显示,分别在66%(8/12)和58%(7/12)的情况下损失3p和9q。 ELST中肾标志物的免疫反应性是重要的诊断警告,以前尚未见报道。实际上,尽管PAX基因复合体和CA-9与内耳发育有关,但目前仍建议使用肾脏标志物以排除转移性RCC。重要的是,以前尚未报告过ELST的拷贝数评估。 ELST中3p的丢失(包括VHL基因座)表明其机制与ccRCC类似。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号